AI reads scans and genes to predict lung cancer drug success

NCT ID NCT07287904

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study uses artificial intelligence to analyze CT scans, pathology slides, and genetic reports from 1,000 lung cancer patients with EGFR mutations. The goal is to build a model that predicts how well targeted therapy will work after surgery. If successful, it could help doctors choose the best treatment for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this AI model could help doctors better predict which lung cancer patients will benefit most from targeted therapy, leading to more personalized treatment.
What could go wrong
This is a retrospective study, meaning it looks back at past data, not a prospective trial. The AI model may not work as well in real-world settings or on new patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Wuhan Union Hospital

    Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.